Accelerating Identification and Regulatory Approval of Investigational Cancer Drugs
- 21 December 2011
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 306 (23), 2608-2609
- https://doi.org/10.1001/jama.2011.1837
Abstract
The development of new drugs is becoming increasingly expensive—and oncology drugs, in particular, have a high clinical failure rate. The current return on capiKeywords
This publication has 3 references indexed in Scilit:
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational DrugsCancer Cell, 2010
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyCancer Cell, 2009
- Economics of New Oncology Drug DevelopmentJournal of Clinical Oncology, 2007